Objectives: To assess the accuracy of point-of-care (POC) measurements of capillary blood glucose and glycosylated haemoglobin (HbA1c) levels in a remote Aboriginal community with high diabetes prevalence.
Design: Cross-sectional study comparing POC capillary glucose and HbA1c results with those from corresponding venous samples measured in a reference laboratory.
Participants and setting: 152 residents aged 11–76 years (representing 76% of population aged over 11 years) had POC glucose measurement in November 2003; 88 with POC glucose level ≥ 5.0 mmol/L, or self-reported diabetes, had POC HbA1c and laboratory glucose and HbA1c measurements.
Main outcome measures: POC fasting capillary levels of glucose (HemoCue Glucose 201 analyser, Medipac Scientific, Sydney) and HbA1c (DCA 2000+ analyser, Bayer Australia, Melbourne); correlation and mean difference between capillary POC and venous blood laboratory measurements of glucose and HbA1c.
Results: Mean and median POC capillary glucose levels were 7.99 mmol/L and 6.25 mmol/L, respectively, while mean and median laboratory venous plasma glucose concentrations were 7.63 mmol/L and 5.35 mmol/L. Values for POC capillary HbA1c and laboratory HbA1c were identical: mean, 7.06%; and median, 6.0%. The correlation coefficient r for POC and laboratory results was 0.98 for glucose and 0.99 for HbA1c. The mean difference in results was 0.36 mmol/L for glucose (95% CI, 0.13–0.62; limits of agreement [LOA], − 2.07 to 2.79 mmol/L; P = 0.007) and < 0.01% for HbA1c (95% CI, − 0.07% to 0.07%; LOA, − 0.66% to 0.66%; P = 0.95), respectively.
Conclusions: POC capillary HbA1c testing, in particular, offers an accurate, practical, community-friendly way of monitoring diabetes in rural and remote clinical settings. POC capillary glucose results should be confirmed by a laboratory test of venous plasma if the results are likely to significantly influence clinical decisions.
- 1. The health and welfare of Australia’s Aboriginal and Torres Strait Islander peoples 2003. Canberra: Australian Bureau of Statistics, Australian Institute of Health and Welfare, 2003.
- 2. De Couten M, Hodge A, Docose G, et al. Review of the epidemiology, aetiology, pathogenesis and preventability of diabetes in Aboriginal and Torres Strait Islander populations. Canberra: Office for Aboriginal and Torres Strait Islander Health Services, Commonwealth Department of Health and Family Services, 1998.
- 3. Daniel M, Rowley KG, McDermott R, et al. Diabetes incidence in an Australian Aboriginal population. An 8-year follow-up study. Diabetes Care 1999; 22: 1993-1998.
- 4. Shephard M, Gill J. Results of an innovative education, training and quality assurance program for point-of-care HbA1c testing using the Bayer DCA 2000 in Australian Aboriginal community controlled health services. Clin Biochem Rev 2003; 24: 123-131.
- 5. Shephard M, Mundraby K. Assisting diabetes management through point-of-care HbA1c testing - the ‘QAAMS’ program for Aboriginal health workers. Aborig Isl Health Work J 2003; 27: 12-18.
- 6. National Health and Medical Research Council. National evidence based guidelines for the management of type 2 diabetes mellitus. Primary prevention, case detection and diagnosis, 2001. Available at: http://www.health.gov.au/nhmrc/publications/pdf/cp86.pdf (accessed Apr 2005).
- 7. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance, 1999.
- 8. The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
- 9. John WG, Edwards R, Price CP. Laboratory evaluation of the DCA 2000 clinic HbA1c immunoassay analyser. Ann Clin Biochem 1994; 31: 367-370.
- 10. Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001; 47: 1985-1992.
- 11. SAS Institute. JMP software release 5.01. Cary, NC: SAS Institute.
- 12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
- 13. White GH, Farrance I. Uncertainty of measurement in quantitative medical testing. Clin Biochem Rev 2004; 25 Suppl 2: S1-S24.
- 14. Shephard M. Quality assurance program for DCA 2000 HbA1c testing in Aboriginal medical services. Fourth progress report, cycle 11, July to December 2004. Canberra: Report to the Australian Government Department of Health and Ageing, Diagnostics and Technology Branch, 2004.
- 15. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetes. Diabetes Care 1999; 22: 1785-1789.
- 16. Miller CD, Barnes CS, Phillips LS, et al. Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care 2003; 26: 1158-1163.
- 17. Simmons D. Impact of an integrated approach to diabetes care at the Rumbalara Aboriginal Health Service. Intern Med J 2003; 33: 581-585.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.